Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
55.6M
-
Number of holders
-
32
-
Total 13F shares, excl. options
-
15.9M
-
Shares change
-
+1.43M
-
Total reported value, excl. options
-
$12.5M
-
Value change
-
+$1.13M
-
Number of buys
-
13
-
Number of sells
-
-7
-
Price
-
$0.79
Significant Holders of Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) as of Q3 2024
35 filings reported holding XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q3 2024.
Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) has 32 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 15.9M shares
of 55.6M outstanding shares and own 28.64% of the company stock.
Largest 10 shareholders include Bain Capital Life Sciences Investors, LLC (4.57M shares), Rock Springs Capital Management LP (3M shares), MORGAN STANLEY (1.52M shares), TAKEDA PHARMACEUTICAL CO LTD (1.48M shares), RiverVest Venture Management LLC (1.44M shares), FMR LLC (1.4M shares), VANGUARD GROUP INC (903K shares), GEODE CAPITAL MANAGEMENT, LLC (338K shares), Balyasny Asset Management L.P. (272K shares), and RENAISSANCE TECHNOLOGIES LLC (266K shares).
This table shows the top 32 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.